About Acadia Pharmaceuticals
Acadia Pharmaceuticals is a company based in San Diego (United States) founded in 1993. It operates as a Direct-to-Consumer (D2C). Acadia Pharmaceuticals has raised $44.7 million across 10 funding rounds from investors including ABN AMRO, NIH and HHS. The company has 654 employees. Acadia Pharmaceuticals offers products and services including NUPLAZID® and DAYBUE®. Acadia Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter San Diego, United States
- Employees 654
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website acadia.com/en-us
- Social LinkedIn X
- Legal Name Acadia Pharmaceuticals Inc.
- Annual Revenue$1.07 B (USD)11.87as on Dec 31, 2025
- Net Profit$391 M (USD)72.66as on Dec 31, 2025
- EBITDA$116.57 M (USD)16.38as on Dec 31, 2025
- Total Equity Funding$44.7M (USD)
in 10 rounds
- Latest Funding Round$300M (USD), Post-IPO
Jan 2016
- InvestorsABN AMRO
& 7 more
- Employee Count654
Products & Services of Acadia Pharmaceuticals
Acadia Pharmaceuticals offers a comprehensive portfolio of products and services, including NUPLAZID® and DAYBUE®.
Treatment for Parkinson’s Disease Psychosis is provided by NUPLAZID®.
Therapy for Rett Syndrome is offered through DAYBUE® product.
Funding Insights of Acadia Pharmaceuticals
Acadia Pharmaceuticals has successfully raised a total of $44.7M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $300 million completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $44.7M
- Total Rounds 10
- Last Round Post-IPO — $300M
- First Round $34M
(Jun 1997)
- Investors Count 8
All 10 funding rounds of Acadia Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2016 | $300M | Post-IPO | – | – | – |
| Dec 2012 | $86.39M | Post-IPO | – | – | – |
| Mar 2012 | $322,000 | Grant | – | – | |
| May 2011 | – | Grant | – | – | |
| May 2011 | $600,000 | Grant | – | – | |
| Jan 2011 | $21.07M | Post-IPO | – | – | |
| Nov 2010 | $300,000 | Grant | – | – | |
| Jan 2009 | $830,000 | Grant | – | – | |
| Aug 1998 | $10.7M | Series D | – | – | |
| Jun 1997 | $34M | Series C | – | – |
8 investors in total: 8 institutional.
Investors in Acadia Pharmaceuticals
Acadia Pharmaceuticals has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include ABN AMRO, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
Provision of financing, loans, equity, and insurance for Danish export and investment activities. | – | vf.dk | - | |
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
ABN AMRO is recognized as a personal bank in the digital era. | 1991 | abnamro.com | Amsterdam, Netherlands | |
Administers holiday and hardship funds for Danish employees and employers. | 1980 | ld.dk | Hojbjerg, Denmark | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Acadia Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Acadia Pharmaceuticals
250 people are tracked at Acadia Pharmaceuticals (116 in leadership, 8 in board & advisors, 126 in team); the tracked headcount is 654.
| Name | Role | Group |
|---|---|---|
Stephen Davis | CEO | Leadership |
Steve Davis | CEO | Leadership |
Stephen R. Davis | President & CEO | Leadership |
Mathias Becquart | Head Of Commercial, Strategy And Ops | Leadership |
Lynne Rueter | Executive Director | Leadership |
Christine Hendrick | Director Commercial Operations | Leadership |
Caryn Coin Westenberger | Director Talent Acquisition | Leadership |
Suresh Kandula | Director, Systems And Operations | Leadership |
Kena Colon | Vice President | Leadership |
Jay C. | Associate Director, Commercial Effectiveness And Training | Leadership |
Anagha Gupte Chokshi | Associate Director, IT Business Partner | Leadership |
Francois Laurent - Finance | Senior Director Fp&a | Leadership |
Nancy Andrews | Director - People Business Partner | Leadership |
Kristen Hoskins | Executive Director, Talent & Strategic Execution | Leadership |
Prasoon Pancholi | Vp, Head Of Commercial Insights, Analytics And Operations | Leadership |
Kathie M. Bishop | SVP, Head of Rare Disease and External Innovation | Leadership |
Mark Schneyer | SVP, Business Development and Chief Business Officer | Leadership |
Lambros Chrones | Senior Medical Director, Medical Affairs | Leadership |
Holly Valdiviez | Senior Vice President & Head of Sales | Leadership |
Konstantina Katcheves | Chief Business And Strategy Officer | Leadership |
230 more people are available in the full profile.
Complete people profiles for Acadia Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Acadia Pharmaceuticals
Acadia Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ACAD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 May 2004
- Listed onNASDAQ: ACAD
- Listed entityACADIA Pharmaceuticals Inc.
- Exchange sectorHealth technology
- ISINUS0042251084
- Share price$19.78 (+1.02% on the day) · 2026-10-09
- Market capitalisation$3.41B
- Price to earnings8.9
- EPS (diluted, trailing year)$2.22
- Volume (last session)1,470,247
Financials of Acadia Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.07B | $391.0M | $116.6M |
| 2024 | $957.8M | $226.4M | $100.2M |
| 2023 | $726.4M | -$61.3M | -$67.8M |
| 2022 | $517.2M | -$216.0M | -$221.6M |
| 2021 | $484.1M | -$167.9M | -$167.1M |
Detailed financial statements for Acadia Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Acadia Pharmaceuticals
4 dated milestones of Acadia Pharmaceuticals across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Acadia Pharmaceuticals is founded.
- Funding First funding round of $34.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $300.0M.
Competitors of Acadia Pharmaceuticals
Acadia Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| lundbeck.com | 1915 | Copenhagen, Denmark | – | 393 | Drugs for CNS disorders are developed and advanced. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. | |
| karunatx.com | 2009 | Boston, United States | $132.1M | 339 | Therapies for psychosis and cognitive impairment are developed. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Acadia Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Acadia Pharmaceuticals
The website of Acadia Pharmaceuticals (acadia.com) receives about 37.8K visits a month and ranks #803,210 among all websites worldwide, #959 in Biotechnology and Pharmaceuticals.
- Monthly visits37.8K
▲ 9.4% vs previous month
- Unique visitors14.7K
per month
- Global rank#803,210
among all websites
- Category rank#959
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit2.5
- Average visit1 min 27 sec
- DevicesDesktop 55% · Mobile 45%
Websites whose visitors overlap most with Acadia Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| elevate.bio | 100% | 37.6K | #1,544,839 | View details | |
| mmsholdings.com | 96% | 12.9K | #1,472,608 | View details | |
| revmed.com | 93% | 83.2K | #872,423 | View details | |
| springworkstx.com | 93% | 13.6K | #1,818,175 | View details | |
| telixpharma.com | 93% | 31.7K | #937,266 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 23 similar websites and full traffic analytics for Acadia Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 23 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Acadia Pharmaceuticals
Complete news archive for Acadia Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Acadia Pharmaceuticals
10 companies that operate in the same segment as Acadia Pharmaceuticals (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Acadia Pharmaceuticals
Acadia Pharmaceuticals was founded in 1993 and raised its 1st funding round 4 years after it was founded.
Acadia Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Stephen Davis is the current CEO of Acadia Pharmaceuticals.
Acadia Pharmaceuticals is a funded company, having raised a total of $44.7M across 10 funding rounds to date. The company's 1st funding round was a Series C of $34M, raised on Jun 1997.
Acadia Pharmaceuticals has 654 employees.
Annual revenue of Acadia Pharmaceuticals is $1.07B as on Dec 31, 2025.
Acadia Pharmaceuticals is dedicated to addressing significant challenges in neuroscience by developing innovative therapies for disorders with high unmet needs. Treatments for Parkinsons Disease Psychosis and Rett Syndrome are provided through FDA-approved products like NUPLAZID and DAYBUE. Research and development efforts are directed towards Prader-Willi Syndrome, Alzheimers Disease Psychosis, and other neuropsychiatric conditions. The company operates in the healthcare sector, emphasizing rare and neurological diseases with a commitment to patient support and advancing scientific breakthroughs.
Acadia Pharmaceuticals's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Biohaven Pharmaceutical.
Acadia Pharmaceuticals offers NUPLAZID® and DAYBUE®.
Yes, Acadia Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ACAD.
Acadia Pharmaceuticals has 8 investors. Key investors include ABN AMRO, NIH, HHS, The Michael J. Fox Foundation, and NEA.
Acadia Pharmaceuticals operates through Acadia Pharmaceuticals Inc..